Why Johnson & Johnson May Be the Closest Thing Investors Can Find to a Bulletproof Dividend Stock

Johnson & Johnson continues its 64-year dividend increase streak, outlasting healthcare peers. The company navigated the 1980s Tylenol crisis and recent talcum powder lawsuits. JNJ now focuses on pharmaceuticals and medical devices, sectors with essential demand. Its 2.3% yield exceeds the S&P 500's. Valuation metrics are above five-year averages, deterring value investors.